WinstonWınston
Stryker Corporation logo

Stryker Corporation

SYK
63
Medical - Devices · Healthcare
Price
$319.87
-11.33 (-3.42%)
Market Cap
$122.63B
Winston Score
63
Winston is curious
A decent business — some strong pillars, some weaker.

Stryker makes medical equipment used in hospitals and surgery centers around the world. Its main products include artificial knees and hips, surgical robots, hospital beds, and trauma implants used to fix broken bones. It is one of the largest medical device companies in the world and owns the Mako surgical robot system, which is widely used in joint replacement surgeries.

Stryker earns money by selling its devices and implants directly to hospitals and surgeons, and it also generates recurring revenue from software, service contracts, and replacement parts tied to its installed equipment. The company operates in over 75 countries, with the United States making up the majority of its sales. Its competitive moat comes from deep relationships with surgeons, a broad product portfolio, and the high switching costs once hospitals adopt its systems. The key growth driver is the aging global population, which is expected to increase demand for joint replacement procedures over the coming decades.

Winston Score History

Politician Trades

35 trades / 12mo

17 Congressional buys and 18 sells on SYK in the last 12 months.

Unlock the full Smart Money Map — every trade plotted on the price chart with politicians, amounts and returns since each trade. Founder's Deal is $57/mo locked for life.

Unlock politician trades

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+2.6% YoY

YoY Growth Rate

Slow revenue growth

EPS Growth

+14.0% YoY

YoY Growth Rate

Steady EPS growth

R&D Spend

$1.6B/ year

Rising (+12% vs prior year)

6.3% of revenue

Below sector average (18%)

R&D investment increasing — building for the future

Insider Activity

9.3%ownership

Flat

Insiders holding steady — not selling despite ability to

Cash Position

Cash flow positive

$2.9B cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Company generates more cash than it spends — no dilution risk from fundraising

Growth context

Stryker Corporation is growing revenue at 3% year-over-year. The Winston Score measures business quality today — these growth metrics show what could matter tomorrow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Share count broadly stable

0.0% over 4y

The share count has stayed roughly flat over this period — little dilution or buyback activity.

Diluted shares outstanding: 382.3M (2021) → 382.2M (2025)

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
63.3%
Premium pricing power — 63.3% gross margin
Operating Margin
15.5%
Healthy — 15.5% operating margin
ROCE
2.6%
Weak — 2.6% return on capital

ROIC between 0% and 5%. They earn a few cents back per dollar invested in the business.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
+8.8%
Steady sales growth (8.8% YoY)
EPS YoY
+16.4%
Earnings growing fast (16.4% YoY)

Healthy double-digit earnings growth — what compounders look like.

EPS Consistency
8/8 quarters
Every recent quarter grew earnings vs last year

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
161%
Turns 161% of profit into real cash
FCF Margin
18.1%
Converts sales into free cash efficiently (18.1%)

FCF margin between 10% and 20%. Every $100 in sales becomes $10 to $20 in real cash.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
0.64
Moderate — manageable debt (0.64)
Interest Cover
7.74x
Adequate interest coverage (7.7x)

Interest coverage between 3 and 8. Profits cover interest several times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)
36.6x
Pricey — P/E 36.6

P/E over 35. The market is pricing in heavy, sustained growth.

P/E vs Forward
+18.9
GROWING
Earnings expected to grow meaningfully — cheaper on forward P/E (36.6 → 17.7)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend Yield
1.06%
Small dividend — 1.06% yield

Modest yield. The bulk of any return needs to come from price appreciation.

Dividend Growth
+4.8%
Dividend growing modestly (4.8% YoY)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial